Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation
- 9 January 2015
- journal article
- case report
- Published by Wiley in Transplant Infectious Disease
- Vol. 17 (1), 103-105
- https://doi.org/10.1111/tid.12327
Abstract
Venovenous extracorporeal membrane oxygenation (ECMO) is increasingly used in patients with respiratory failure who fail conventional treatment. Postoperative pneumonia is the most common infection after lung transplantation (40%). Imipenem is frequently used for empirical treatment of nosocomial pneumonia in the intensive care unit. Nevertheless, few data are available on the impact of ECMO on pharmacokinetics, and no data on imipenem dosing during ECMO. Currently, no guidelines exist for antibiotic dosing during ECMO support. We report the cases of 2 patients supported with venovenous ECMO for refractory acute respiratory distress syndrome following single lung transplantation for pulmonary fibrosis, treated empirically with 1 g of imipenem intravenously every 6 h. Enterobacter cloacae was isolated from the respiratory sample of Patient 1 and Klebsiella pneumoniae was isolated from the respiratory sample of Patient 2. Minimum inhibitory concentrations of the 2 isolated strains were 0.125 and 0.25 mg/L, respectively. Both patients were still alive on day 28. This is the first report, to our knowledge, of imipenem concentrations in lung transplantation patients supported with ECMO. This study confirms high variability in imipenem trough concentrations in patients on ECMO and with preserved renal function. An elevated dosing regimen (4 g/24 h) is more likely to optimize drug exposure, and therapeutic drug monitoring is recommended, where available. Population pharmacokinetic studies are indicated to develop evidence-based dosing guidelines for ECMO patients.Keywords
This publication has 8 references indexed in Scilit:
- DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?Clinical Infectious Diseases, 2014
- Incidence of nosocomial pneumonia and risk of recurrence after antimicrobial therapy in critically ill lung and heart–lung transplant patientsClinical Transplantation, 2013
- Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?Journal of Antimicrobial Chemotherapy, 2012
- Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenationCritical Care, 2012
- Pharmacokinetic issues for antibiotics in the critically ill patientCritical Care Medicine, 2009
- The role of carbapenems in the treatment of severe nosocomial respiratory tract infectionsExpert Opinion on Pharmacotherapy, 2008
- Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patientsJournal of Chromatography B: Biomedical Sciences and Applications, 1997